Who are RBX2660's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lactobacillus LB, Lactobacillus Crispatus M247, E. coli Nissle suspension, Lactobacillus casei variety rhamnosus granules, INF108F probiotic, Lactobacillus brevis CD2 Lozenges.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rbx2660.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RBX2660 — Competitive Intelligence Brief

RBX2660 (RBX2660) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product. Area: Infectious Disease / Gastroenterology.

phase 3 Live biotherapeutic product Infectious Disease / Gastroenterology Biologic Live · refreshed every 30 min

Target snapshot

RBX2660 (RBX2660) — Rebiotix Inc.. RBX2660 is a microbiota restoration therapy that repopulates the gut microbiome to treat recurrent Clostridioides difficile infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
RBX2660 TARGET	RBX2660	Rebiotix Inc.	phase 3	Live biotherapeutic product
lactobacillus LB	lactobacillus LB	Hospital General de Mexico	marketed	Live biotherapeutic product / Probiotic
Lactobacillus Crispatus M247	Lactobacillus Crispatus M247	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Live biotherapeutic product
E. coli Nissle suspension	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
Lactobacillus casei variety rhamnosus granules	Lactobacillus casei variety rhamnosus granules	Seoul National University Hospital	marketed	Probiotic / Live biotherapeutic product
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus brevis CD2 Lozenges	Lactobacillus brevis CD2 Lozenges	Next Gen Pharma India Pvt. Ltd.	phase 3	Live biotherapeutic product (probiotic)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product class)

Ardeypharm GmbH · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class
Infant Bacterial Therapeutics · 1 drug in this class
Mikrobiomik Healthcare Company S.L. · 1 drug in this class
OxThera · 1 drug in this class
Rebiotix Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RBX2660 — Competitive Intelligence Brief. https://druglandscape.com/ci/rbx2660. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab